Recombinant EphB4-HSA Fusion Protein

BIOLOGICAL9 trials

Sponsors

University of Southern California, AIDS Malignancy Consortium, Northwestern University

Conditions

ALK Gene MutationAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBRAF Gene MutationBladder Cancer Stage 0Bladder Cancer Stage IBlasts 5 Percent or More of Bone Marrow Nucleated CellsCastration Levels of TestosteroneCastration-Resistant Prostate Carcinoma

Phase 1

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruitingNCT02495896

University of Southern CaliforniaHead and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma +13

Start: 2015-09-03End: 2026-12-31Updated: 2026-04-29

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

TerminatedNCT02767921

University of Southern CaliforniaInfiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage IIA Prostate Cancer +7

Start: 2016-08-02End: 2021-11-15Updated: 2021-11-24

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

TerminatedNCT03519984

University of Southern CaliforniaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm +8

Start: 2018-05-09End: 2020-11-24Updated: 2021-11-30

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

WithdrawnNCT03552796

University of Southern CaliforniaBladder Cancer Stage 0, Bladder Cancer Stage I, Recurrent Bladder Carcinoma

Start: 2023-08-01End: 2025-08-01Updated: 2023-06-26

Phase 2

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Active, not recruitingNCT02717156

University of Southern CaliforniaProstate Cancer, Stage IV Bladder Urothelial Carcinoma, Urothelial Carcinoma

Start: 2016-11-21End: 2030-12-31Updated: 2026-06-09

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

CompletedNCT02799485

AIDS Malignancy ConsortiumSkin Kaposi Sarcoma

Start: 2018-02-13End: 2025-02-19Updated: 2026-06-01

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

CompletedNCT03049618

University of Southern CaliforniaALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation +9

Start: 2017-03-10End: 2024-09-04Updated: 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

TerminatedNCT03146871

University of Southern CaliforniaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome +2

Start: 2017-04-20End: 2019-03-27Updated: 2026-06-08

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Northwestern UniversityCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents +7

Start: 2019-09-20End: 2022-06-30Updated: 2022-04-27

Related Papers

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2022-02-16

Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.

Journal of Clinical Oncology2021-05-202 citations

A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC).

Journal of Clinical Oncology2020-05-202 citations

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-191 citations